ATE460176T1 - Mikrosomvakzin - Google Patents

Mikrosomvakzin

Info

Publication number
ATE460176T1
ATE460176T1 AT04743611T AT04743611T ATE460176T1 AT E460176 T1 ATE460176 T1 AT E460176T1 AT 04743611 T AT04743611 T AT 04743611T AT 04743611 T AT04743611 T AT 04743611T AT E460176 T1 ATE460176 T1 AT E460176T1
Authority
AT
Austria
Prior art keywords
vaccin
microsome
mhc
fragments
protein
Prior art date
Application number
AT04743611T
Other languages
English (en)
Inventor
Ping Wang
Suling Li
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Application granted granted Critical
Publication of ATE460176T1 publication Critical patent/ATE460176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04743611T 2003-08-01 2004-07-30 Mikrosomvakzin ATE460176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318096.5A GB0318096D0 (en) 2003-08-01 2003-08-01 Vaccine
PCT/GB2004/003285 WO2005011730A1 (en) 2003-08-01 2004-07-30 Microsome vaccine

Publications (1)

Publication Number Publication Date
ATE460176T1 true ATE460176T1 (de) 2010-03-15

Family

ID=27799668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743611T ATE460176T1 (de) 2003-08-01 2004-07-30 Mikrosomvakzin

Country Status (9)

Country Link
US (2) US7498046B2 (de)
EP (1) EP1648498B1 (de)
JP (1) JP4903043B2 (de)
CN (1) CN1856322A (de)
AT (1) ATE460176T1 (de)
DE (1) DE602004025943D1 (de)
GB (1) GB0318096D0 (de)
HK (1) HK1093014A1 (de)
WO (1) WO2005011730A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781777A1 (de) * 2004-07-02 2007-05-09 Avaris AB Verfahren zur genetischen aktivierung von zellen sowie verwendungen für die zellen
GB0502065D0 (en) * 2005-02-01 2005-03-09 Queen Mary & Westfield College Assay method
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465A1 (de) 2007-07-03 2020-03-11 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
EP2250189A4 (de) * 2008-02-26 2012-07-04 Univ California Gylcopeptide sowie verfahren zu ihrer herstellung und verwendung
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US8435538B2 (en) * 2008-04-10 2013-05-07 Thrombosis Research Institute Anti-atheroma vaccine
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
US7821149B2 (en) * 2008-09-18 2010-10-26 Moshe Meller Airborne stabilized wind turbines system
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
CA2742324A1 (en) 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
CN103690928B (zh) * 2009-01-08 2016-04-20 株式会社癌免疫研究所 新型癌抗原eEF2
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
PT3173427T (pt) 2011-03-31 2019-09-17 Adc Therapeutics Sa Anticorpos contra antigénio associado ao rim 1 e fragmentos de ligação a antigénio dos mesmos
NZ625758A (en) 2012-01-09 2016-05-27 Alethia Biotherapeutics Inc Method for treating breast cancer
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
BR112021007508A2 (pt) * 2018-10-21 2021-08-10 Kansas State University Research Foundation método para modificar por engenharia um alvo biológico, composição, método de ativação de células e dispositivos microfluídicos
CN110922492B (zh) * 2019-12-18 2022-02-15 重庆医科大学 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法
WO2023156532A1 (en) * 2022-02-18 2023-08-24 Servicio Andaluz De Salud ISOLATED PLASMA MEMBRANE-DERIVED VESICLES (PMdV) FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230424A (en) 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
DE69942100D1 (de) * 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2001096377A2 (en) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
WO2002030964A2 (en) * 2000-10-10 2002-04-18 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from mhc positive cells
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells

Also Published As

Publication number Publication date
US20070184022A1 (en) 2007-08-09
EP1648498B1 (de) 2010-03-10
GB0318096D0 (en) 2003-09-03
JP2007501207A (ja) 2007-01-25
HK1093014A1 (en) 2007-02-23
JP4903043B2 (ja) 2012-03-21
US7498046B2 (en) 2009-03-03
DE602004025943D1 (de) 2010-04-22
US20090232766A1 (en) 2009-09-17
CN1856322A (zh) 2006-11-01
EP1648498A1 (de) 2006-04-26
WO2005011730A1 (en) 2005-02-10
WO2005011730A8 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
HK1093014A1 (en) Microsome vaccine
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
RS54127B1 (en) ANTIBODIES NEUTRALIZERS OF THE HUMAN FACTOR OF STIMULATION OF THE COLONIA OF THE GRANULLocyte MACROPHAGUS
FR20C1016I1 (de)
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
DK1691824T3 (da) Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter
DK1620456T3 (da) Hla-a2 tumor-associerede antigen-peptider og præparater
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
CR8231A (es) Anticuerpos rg1 y uso de los mismos
EP1490094A4 (de) Antikörper-fusionsproteine: wirksame adjuvantien bei der proteinvakzination
DE602004025668D1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK1670823T3 (da) Kimært mhc-protein og oligomer deraf til specifik målretning
ATE542140T1 (de) Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
NO20044105L (no) VEGF peptider og anvendelse derav
DE60324816D1 (de) Impfstoffe gegen allergien
ATE506433T1 (de) Prozessierung von peptiden und proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties